Molecular diagnostics company Yourgene Health has launched the Yourgene Insight DPYD assay. The assay uses genetic insights for safer chemotherapy treatments to align with updated testing guidelines.
“The new kit delivers a deeper insight and greater confidence for clinical decision-making, helping reduce adverse side effects while improving patient safety,” said CEO of parent company Novacyt Lyn Rees.
Yourgene Inishgt DPYD is a genotyping test that can identify cancer patients with dihydropyrimidine dehydrogenase (DPD) deficiency, which can cause severe and even deadly side effects in patients treated with chemotherapeutic drug 5-fluorouracil (5-FU).
5-FU is commonly used to treat colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients worldwide are treated with fluoropyrimidines, including 5-FU annually. Of these patients, 10% to 20% suffer side effects associated with DPD deficiency. Screening patients for DPYD variants supports treatments tailored to patient needs.
The Yourgene Insight DPYD test has the same ARMS (amplification refractory mutation system) allele specific amplification workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day.
